Vacciner contre le virus respiratoire syncytial ? Quel rapport bénéfice/risque ?

Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection and hospitalization in children. Globally, in 2019, there were an estimated 33 million acute respiratory infections associated with RSV, resulting in 3.6 million pediatric hospitalizations. People 65 years and older are also at risk for severe RSV infection with an estimated 5.2 million cases, 470,000 hospitalizations, and 33,000 hospital deaths among adults ≥ 60 years in high-income countries pupil. A vaccine has just been authorized for pregnant women to prevent RSV infections in infants and two other vaccines (only one of which is marketed in France) for the elderly. What to expect from vaccination? How effective? How long does the protection last? What side effects? [ABSTRACT FROM AUTHOR]